LTR Pharma Says Participants Using Intranasal Tech Reported Normal Erectile Function; Shares Down 6%

MT Newswires Live

Feb 02

LTR Pharma (ASX:LTP) said that participants using Spontan, its intranasal erectile dysfunction product, reported normal erectile function during masturbation but intermittent difficulty maintaining erections during partnered sexual activities, according to a Monday filing with the Australian bourse.

The participants also reported adverse effects such as mild-to-moderate, transient nasal discomfort and sneezing, which resolved within five minutes, the filing said.

The nasal symptoms were reduced with repeated use of the product over a two-week period, the filing added.

The company said it plans to evaluate the potential for a clinician-initiated clinical study in men with sexual performance anxiety or situational erectile difficulties in the coming year.

LTR Pharma's shares fell 6% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608739831"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608739831\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608739831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 12:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608739831","market":"fut","top_or_hot":-1,"title":"LTR Pharma Says Participants Using Intranasal Tech Reported Normal Erectile Function; Shares Down 6%","media":"MT Newswires Live","content":"<html><body><p> LTR Pharma (ASX:LTP) said that participants using Spontan, its intranasal erectile dysfunction product, reported normal erectile function during masturbation but intermittent difficulty maintaining erections during partnered sexual activities, according to a Monday filing with the Australian bourse.</p><p>The participants also reported adverse effects such as mild-to-moderate, transient nasal discomfort and sneezing, which resolved within five minutes, the filing said.</p><p>The nasal symptoms were reduced with repeated use of the product over a two-week period, the filing added.</p><p>The company said it plans to evaluate the potential for a clinician-initiated clinical study in men with sexual performance anxiety or situational erectile difficulties in the coming year.</p><p>LTR Pharma's shares fell 6% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LTR Pharma Says Participants Using Intranasal Tech Reported Normal Erectile Function; Shares Down 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLTR Pharma Says Participants Using Intranasal Tech Reported Normal Erectile Function; Shares Down 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-02 12:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> LTR Pharma (ASX:LTP) said that participants using Spontan, its intranasal erectile dysfunction product, reported normal erectile function during masturbation but intermittent difficulty maintaining erections during partnered sexual activities, according to a Monday filing with the Australian bourse.</p><p>The participants also reported adverse effects such as mild-to-moderate, transient nasal discomfort and sneezing, which resolved within five minutes, the filing said.</p><p>The nasal symptoms were reduced with repeated use of the product over a two-week period, the filing added.</p><p>The company said it plans to evaluate the potential for a clinician-initiated clinical study in men with sexual performance anxiety or situational erectile difficulties in the coming year.</p><p>LTR Pharma's shares fell 6% in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LTP.AU","symbol_name":"LTR PHARMA LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608739831","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608739831","pubTimestamp":1770006150,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LTR Pharma  said that participants using Spontan, its intranasal erectile dysfunction product, reported normal erectile function during masturbation but intermittent difficulty maintaining erections during partnered sexual activities, according to a Monday filing with the Australian bourse.The participants also reported adverse effects such as mild-to-moderate, transient nasal discomfort and sneezing, which resolved within five minutes, the filing said.The nasal symptoms were reduced with repeated use of the product over a two-week period, the filing added.The company said it plans to evaluate the potential for a clinician-initiated clinical study in men with sexual performance anxiety or situational erectile difficulties in the coming year.LTR Pharma's shares fell 6% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LTP.AU":"LTR PHARMA LTD","BK7096":"制药"},"translate_title":"LTR Pharma表示，使用鼻内技术的参与者报告勃起功能正常；股价下跌6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTP.AU":1},"content_text":"LTR Pharma (ASX:LTP) said that participants using Spontan, its intranasal erectile dysfunction product, reported normal erectile function during masturbation but intermittent difficulty maintaining erections during partnered sexual activities, according to a Monday filing with the Australian bourse.The participants also reported adverse effects such as mild-to-moderate, transient nasal discomfort and sneezing, which resolved within five minutes, the filing said.The nasal symptoms were reduced with repeated use of the product over a two-week period, the filing added.The company said it plans to evaluate the potential for a clinician-initiated clinical study in men with sexual performance anxiety or situational erectile difficulties in the coming year.LTR Pharma's shares fell 6% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}